Equities

GSK plc

GSK:LSE

GSK plc

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,309.50
  • Today's Change9.50 / 0.73%
  • Shares traded5.88m
  • 1 Year change-7.61%
  • Beta0.6085
Data delayed at least 20 minutes, as of Nov 21 2024 16:28 GMT.
More ▼

Profile data is unavailable for this security.

About the company

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

  • Revenue in GBP (TTM)31.31bn
  • Net income in GBP2.51bn
  • Incorporated1999
  • Employees70.21k
  • Location
    GSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
  • Phone+44 20 8047 5000Fax+44 20 8047 7807
  • Websitehttps://www.gsk.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		GSK:LSE since
announced		Transaction
value
Aiolos Bio IncDeal completed09 Jan 202409 Jan 2024Deal completed-15.46%1.40bn
Data delayed at least 20 minutes, as of Nov 21 2024 16:28 GMT.

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Haleon PLC11.24bn1.21bn33.37bn24.00k33.37bn24.00k
Takeda Pharmaceutical Co Ltd23.37bn1.49bn34.20bn49.28k34.20bn49.28k
Jiangsu Hengrui Pharmaceuticals Co Ltd2.85bn597.96m35.33bn19.61k35.33bn19.61k
Sun Pharmaceutical Industries Ltd4.73bn1.04bn40.08bn43.00k40.08bn43.00k
Daiichi Sankyo Co Ltd9.04bn1.29bn45.06bn18.73k45.06bn18.73k
Merck KGaA17.44bn2.24bn49.96bn62.26k49.96bn62.26k
GSK plc31.31bn2.51bn53.89bn70.21k53.89bn70.21k
Chugai Pharmaceutical Co Ltd5.87bn1.99bn55.10bn7.60k55.10bn7.60k
Zoetis Inc7.27bn1.93bn62.96bn14.10k62.96bn14.10k
CSL Ltd11.72bn2.09bn68.70bn30.40k68.70bn30.40k
Data as of Nov 21 2024. Currency figures normalised to GSK plc's reporting currency: UK Pound GBX

Institutional shareholders

20.24%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 01 Oct 2024141.67m3.42%
BlackRock Fund Advisorsas of 01 Oct 2024125.85m3.04%
Dodge & Coxas of 23 Feb 202499.38m2.40%
Schroder Investment Management Ltd.as of 01 Oct 202486.96m2.10%
Wellington Management Co. LLPas of 01 Oct 202478.23m1.89%
Norges Bank Investment Managementas of 01 Oct 202477.39m1.87%
Legal & General Investment Management Ltd.as of 01 Oct 202466.37m1.60%
BlackRock Advisors (UK) Ltd.as of 01 Oct 202465.44m1.58%
Silchester International Investors LLPas of 01 Oct 202449.13m1.19%
SSgA Funds Management, Inc.as of 01 Oct 202448.74m1.18%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.